参考文献/References:
[1] Elkin VD,Sedova TG,Kopytova EA,et al.Langerhans cell histiocytosis: skin diseases and visceral lesions[J].Ter Arkh,2017,89(4):115-120.DOI:10.17116/terarkh2017894115-120.
[2] Salotti J. Epidemiology of Langerhans cell histiocytosis:onwards and upwards![J].Pediatr Blood Cancer,2008,51(1):3-4. DOI:10.1002/pbc.21552.
[3] Satter EK,High WA.Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society[J].Pediatr Dermatol,2008,25(3):291-295.DOI:10.1111/j.1525-1470.2008.00669.x.
[4] Vassallo R,Ryu JH, Colby TV,et al. Pulmonary Langerhans' cell histiocytosis[J]. N Engl J Med,2000,342(26):1969-1978.DOI:10.1056/NEJM200006293422607.
[5] Cantu MA,Lupo PJ,Bilgi M,et al.Optimal therapy for adults with Langerhans cell histiocytosis bone lesions[J].PLoS One,2012,7(8):e43257.DOI:10.1371/journal.pone.0043257.
[6] Chayapathi V,Mahajan A,Kalra M.Refractory LCH with secondary intracranial PNET: a case report and review of literature[J].J Pediatr Hematol Oncol,2018,40(2):e117-e120.DOI:10.1097/MPH.0000000000000927.
[7] Atarguine H,Hocar O,Oussmane S,et al.Multisystem Langerhans cell histiocytosis in adults revealed by skin lesions[J].Skinmed,2016,14(2):147-149.
[8] Kotecha R,Venkatramani R,Jubran RF,et al.Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis[J].Am J Clin Oncol,2014,37(6):592-596.DOI:10.1097/COC.0b013e318281d6ce.
[9] Lindahl LM,Fenger-Grøn M,Iversen L.Topical nitrogen mustard therapy in patients with Langerhans cell histiocytosis[J].Br J Dermatol,2012,166(3):642-645.DOI:10.1111/j.1365-2133.2011.10673.x.
[10] Abraham A,Alsultan A,Jeng M,et al.Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis[J].Pediatr Blood Cancer,2013,60(6):E19-E22.DOI:10.1002/pbc.24436.